e-learning resources

ERS International Congress, Milan 2017

Browse by day: Saturday, 09.09.2017 Sunday, 10.09.2017 Monday, 11.09.2017 Tuesday, 12.09.2017 Wednesday, 13.09.2017		Sponsored symposia: Industry Evening Symposium at ERS 2017: “Evolving Concepts in Asthma with Type 2 Inflammation: the Role of Biologics”

Citations should be made in the following way: Authors. Title. Eur Respir J 2017; 50: Suppl. 61, abstract number.

Bronchodilators and bronchoprotectors

Poster Discussion
Chairs: K. Chung (London, United Kingdom), K. Rabe (Grosshansdorf, Germany)

Download all media

Download all media

Tiotropium bromide: Efficacy and safety in complex treatment of COPD M. Kulynych-Miskiv (Galych, Ukraine)
A randomized placebo and active controlled trial of AZD8871 a novel dual acting bronchodilator in COPD patients D. Singh (Manchester, United Kingdom)
Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma S. Jabbal (Dundee, United Kingdom)
Smart Watch-based Coaching with Tiotropium and Olodaterol Ameliorates Physical Activity in Chronic Obstructive Pulmonary Disease Patients E. Gabazza (Tsu-Mie, Japan)
Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) in patients with moderate COPD: Results from the CRYSTAL study T. Greulich (Marburg, Germany)
Delayed time to first and subsequent exacerbations independent of season with indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone (SFC): the FLAME study K. Chapman (Toronto, ON, Canada)
Indacaterol/glycopyrronium (IND/GLY) reduces days with COPD exacerbation vs salmeterol/fluticasone (SFC) independent of PRO tool: results of the FLAME study J. Wedzicha (London, United Kingdom)
Bronchoprotective activity and safety evaluation of the novel antimuscarinic/ß2 agonist (MABA) CHF6366 in dogs C. Carnini (Parma, Pr, Italy)
In vitro pharmacological characterization of the novel inhaled bronchodilator CHF6366 acting as dual muscarinic antagonist/ß2-agonist (MABA) F. Pastore (PARMA (PR), Italy)
Contractile effects of NaV1.5 current in rabbit bronchial smooth muscle. k. Thornbury (Dundalk, Ireland)
N-Acetylcysteine protects human bronchi via inhibiting neurokinin A L. Calzetta (Roma, Rm, Italy)
The impact of tiotropium for exercise induced bronchoconstriction K. Terada (Himeji city, Japan)
Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial C. Wong (Auckland, New Zealand)
Interaction between tiotropium bromide and olodaterol in human bronchial smooth muscle M. Cazzola (Roma, Rm, Italy)
A randomized placebo controlled trial of AZD8871 a novel dual acting bronchodilator in asthmatics. E. Jimenez Lozano (Barcelona, Spain)
Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD G. Ferguson (Farmington Hills, United States of America)
One year change in health status in patients with stable Chronic Obstructive Pulmonary Disease (COPD) under long-acting bronchodilators treatment C. Wang (Beijing, China)
Clinical synergism of LABA/LAMA combinations in COPD patients P. Rogliani (Roma, Rm, Italy)

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.